Switching from Rivaroxaban to Apixaban
When switching from rivaroxaban to apixaban, discontinue rivaroxaban and start apixaban at the time of the next scheduled rivaroxaban dose—no washout period or bridging with low-molecular-weight heparin is required. 1
Direct Switching Protocol
The FDA-approved apixaban prescribing information provides explicit guidance for this transition 1:
- Stop rivaroxaban at its regularly scheduled time
- Start apixaban when the next dose of rivaroxaban would have been due
- No bridging anticoagulation is needed during this transition
- No washout period is necessary
This straightforward approach applies regardless of whether the indication is atrial fibrillation or venous thromboembolism.
Dosing Considerations by Indication
For Atrial Fibrillation
Start apixaban at 5 mg twice daily, unless the patient meets dose-reduction criteria (any 2 of: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL), in which case use 2.5 mg twice daily 2, 3, 4.
For Venous Thromboembolism Treatment
The dosing depends on timing:
- If within the first 7 days of VTE treatment: Start apixaban at 10 mg twice daily to complete the initial treatment phase 5
- If beyond 7 days of treatment: Start apixaban at 5 mg twice daily 5
- For extended VTE prophylaxis (after ≥6 months): Consider 2.5 mg twice daily 5
Pharmacologic Rationale
This seamless transition is possible because both rivaroxaban and apixaban are direct factor Xa inhibitors with:
- Similar mechanisms of action (both inhibit factor Xa directly)
- Rapid onset (peak effect within 2-4 hours) 6
- Short half-lives (rivaroxaban 5-9 hours, apixaban 12 hours) 7, 4
- Predictable pharmacokinetics without need for overlap 7
The guideline consensus across multiple sources 7, 8 confirms that switching between direct oral anticoagulants does not require heparin bridging, unlike transitions involving warfarin.
Critical Pitfalls to Avoid
Do not use LMWH bridging—this increases bleeding risk without benefit when switching between DOACs 5. Bridging is only indicated when transitioning to/from warfarin or in specific high-risk scenarios (e.g., within 3 months of acute VTE requiring procedural interruption) 5.
Do not create a gap in anticoagulation—the timing should be seamless to avoid thrombotic risk 1. The next-dose timing ensures continuous anticoagulant coverage given the overlapping pharmacodynamic effects.
Verify renal function—both agents require dose adjustment in renal impairment, though apixaban has less renal dependence (27% renal excretion) compared to rivaroxaban (66% renal excretion) 4. This may be a reason for switching in patients with declining renal function.
Confirm appropriate indication-specific dosing—VTE treatment doses differ from atrial fibrillation doses, and using the wrong regimen compromises efficacy 5.